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ABSTRACT
ObjeCtive
To assess the potential association between prenatal 
use of antidepressants and the risk of attention-
deficit/hyperactivity disorder (ADHD) in offspring.
Design
Population based cohort study.
setting
Data from the Hong Kong population based electronic 
medical records on the Clinical Data Analysis and 
Reporting System.
PartiCiPants
190 618 children born in Hong Kong public hospitals 
between January 2001 and December 2009 and 
followed-up to December 2015.
Main OutCOMe Measure
Hazard ratio of maternal antidepressant use during 
pregnancy and ADHD in children aged 6 to 14 years, with an 
average follow-up time of 9.3 years (range 7.4-11.0 years).
results
Among 190 618 children, 1252 had a mother who used 
prenatal antidepressants. 5659 children (3.0%) were 
given a diagnosis of ADHD or received treatment for 
ADHD. The crude hazard ratio of maternal 
antidepressant use during pregnancy was 2.26 (P<0.01) 
compared with non-use. After adjustment for potential 
confounding factors, including maternal psychiatric 
disorders and use of other psychiatric drugs, the 
adjusted hazard ratio was reduced to 1.39 (95% 
confidence interval 1.07 to 1.82, P=0.01). Likewise, 
similar results were observed when comparing children 
of mothers who had used antidepressants before 
pregnancy with those who were never users (1.76, 1.36 
to 2.30, P<0.01). The risk of ADHD in the children of 
mothers with psychiatric disorders was higher 
compared with the children of mothers without 
psychiatric disorders even if the mothers had never 
used antidepressants (1.84, 1.54 to 2.18, P<0.01). All 
sensitivity analyses yielded similar results. Sibling 
matched analysis identified no significant difference in 
risk of ADHD in siblings exposed to antidepressants 
during gestation and those not exposed during 
gestation (0.54, 0.17 to 1.74, P=0.30).
COnClusiOns
The findings suggest that the association between 
prenatal use of antidepressants and risk of ADHD in 
offspring can be partially explained by confounding by 
indication of antidepressants. If there is a causal 
association, the size of the effect is probably smaller 
than that reported previously.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a 
common neurodevelopmental disorder in children and 
adolescents. It is characterised by pervasive hyperactiv-
ity, inattention, and impulsiveness, which impairs the 
lives of young people.1  ADHD is common among school 
aged children, with a worldwide prevalence of 5-7%.2 3 
Rates of diagnosis are high in North America and, while 
ADHD is under-diagnosed in most other parts of the 
world, rates of identified cases are increasing.2  Owing 
to early onset, lifelong persistence, and high levels of 
comorbidities and impairment associated with ADHD,4 
its negative impact on social outcomes, education, and 
the health of patients and their caregivers is substan-
tial.5 Understanding the risk factors for ADHD is an 
important public health matter.
Recent studies have suggested a potential association 
between maternal prenatal use of antidepressants, in 
particular selective serotonin reuptake inhibitors 
(SSRIs), and the risk of ADHD in children.6-11  A system-
atic literature search identified six observational stud-
ies, including three cohort studies6 9 11  and three 
case-control studies,7 8 10  which investigated the associ-
ation between antidepressant use in pregnancy and 
ADHD in children, with the study populations from 
Scandinavian countries or North America. However, 
findings were inconsistent.6-11  Only one  case-control 
study7  restricted its sample to children aged at least 5 
years, whereas the others did not.6-11  As ADHD is usually 
diagnosed clinically after age 5 years, previous studies 
might have identified unrepresentative samples because 
of large numbers of children aged less than 5  years, 
leading to biased estimates of the actual risk. Further-
more, a controversial issues is whether the observed 
association between antidepressant use in pregnancy 
WhAT IS AlReAdy knoWn on ThIS TopIC
Whether to prescribe drugs for depression during pregnancy is a complex decision
Prenatal use of antidepressants is considered a risk factor for attention-deficit/
hyperactivity disorder (ADHD) in children, but evidence is inconclusive
The negative consequences of untreated maternal depression might also affect 
childhood development
WhAT ThIS STudy AddS
The risk of ADHD was similar between the offspring of mothers who used 
antidepressants during pregnancy and those who used before pregnancy only, 
whereas the risk was higher for offspring of mothers with psychiatric disorders 
irrespective of whether antidepressants were used
Evidence suggests that the association between prenatal antidepressant use and 
risk of ADHD may at least partially be explained by confounding by indication of 
antidepressants
If there was a causal association; then the size of the effect is probably smaller than 
what has been reported previously
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and ADHD in childhood is causal or may be confounded 
by other “third factor” variables, such as underlying 
maternal psychiatric disorder (confounding by indica-
tion). ADHD is highly heritable and often comorbid with 
other mental health problems, including anxiety and 
depression, both of which are commonly treated with 
antidepressants.12  The association between prenatal use 
of antidepressants and ADHD in offspring could there-
fore be confounded by maternal or paternal psychiatric 
disorders.7 13  A recently published study using informa-
tion from a Swedish registry found an increased risk of 
ADHD in offspring with prenatal exposure to antidepres-
sants using population wide analyses. However, the 
authors reported non-significant results in sibling 
matched analyses and recommended that future 
research should use designs to help account for unmea-
sured genetic and familial confounders to explore the 
associations with prenatal exposure to antidepressants 
in other countries.11 Studies to date have not adequately 
addressed the critical question of confounding by indi-
cation. We hypothesised that the apparent link between 
prenatal use of antidepressants, including SSRIs, and 
the increased risk of ADHD in offspring is at least partly 
confounded by maternal risk factors. Consequently, we 
assessed the association between maternal prenatal use 
of antidepressants and the risk of ADHD in offspring, 
and in particular the possibility of confounding by indi-
cation in this association by examining the effect of 
pre-existing maternal psychiatric illness.
Methods
Data source and study design
We carried out a cohort study nested in the electronic 
health record of the Clinical Data Analysis and Report-
ing System (CDARS), a territory wide database in Hong 
Kong. CDARS was developed by the Hong Kong Hospital 
Authority, a statutory body that manages all public hos-
pitals and their associated ambulatory clinics in Hong 
Kong. The hospital authority health service is accessi-
ble to all Hong Kong residents (over 7 million). Data 
from CDARS have been used for various pharmacoepi-
demiological studies.14-18  The database contains patient 
specific data, including personal information, payment 
method, prescription information, pharmacy dispens-
ing information, diagnosis, laboratory test results, and 
admission and discharge information.19  CDARS con-
tains the records of all in-patient, out-patient, and 
emergency room admissions in hospital authority clin-
ics and hospitals since 1995. Records are coded to pro-
tect patient confidentiality. A detailed description of 
CDARS can be found elsewhere.16
source population
The source population included all children born in 
public hospitals in Hong Kong between 1 January 2001 
and 31 December 2009. Therefore by 31 December 2015, 
when we collected the child outcome data, all children 
would have at least six years’ follow-up. To avoid poten-
tial bias we excluded children without valid moth-
er-child linkage, born to mothers who were non-Hong 
Kong residents and whose medical records were likely 
to be incomplete (18.8%, 45 831 out of 243 526 children). 
Only live births were included in the analysis. We 
defined a valid mother-child linkage as an exact match 
of mother and child patient identification numbers, 
delivery date, and delivery hospital. The mother-child 
linkage is created by the hospital authority for clinical 
management, and the mother and child records are 
linked permanently immediately after delivery; hence 
this linkage is highly accurate.
Pregnancy period and maternal antidepressant use
We identified prenatal antidepressant use in mothers 
with respect to the pregnancy period. The gestational 
age of pregnancy is directly recorded by healthcare pro-
fessionals, and the last menstrual period was calcu-
lated by date of delivery minus gestational age at 
delivery. We defined the pregnancy period as the period 
between the last menstrual period and the date of deliv-
ery, with the date of the last menstrual period as the 
start of cohort entry, and we defined the time before the 
last menstrual period as prepregnancy. To examine any 
potential effects on the timing of antidepressant use, we 
further divided the pregnancy period into trimesters: 
first trimester, 0-90 days after the last menstrual period; 
second trimester, 91-180 days after the last menstrual 
period; and third trimester, 181 days after the last men-
strual period to delivery.
Antidepressant use in mothers was extracted from the 
prescribing and dispensing records in CDARS. All drugs in 
the British National Formulary chapter 4.3 were included. 
We defined antidepressant use as the length of time using 
the drugs, and this was estimated by the length of time 
between start and end dates for each prescription as 
recorded in CDARS. When end dates for prescriptions 
were missing we used the median treatment duration to 
impute data. The rate of missing data is low, with 98.4% 
of antidepressant prescriptions having complete informa-
tion about treatment duration. Children were considered 
to have been exposed prenatally during the respective 
risk window if maternal use of drugs overlapped with a 
time point in the pregnancy window. Based on maternal 
antidepressant use in different risk periods, we classified 
the children into four groups: those with mothers who 
used drugs before conception but who stopped treatment 
when pregnant (preconception users), or negative control 
group 1; those who never used drugs before and during 
pregnancy, or never users (in subgroup analyses we fur-
ther classified this group into (a) never users without psy-
chiatric disorders, and (b) never users with psychiatric 
disorders, or negative control group 2); those whose 
mothers were non-gestational users (a combined group of 
never users and preconception users); and those whose 
mothers used antidepressants during pregnancy (gesta-
tional users), or the active treatment group.
Through CDARS we also identified maternal psychiat-
ric disorders diagnosed before and during pregnancy. 
We coded these using ICD-9-CM (international classifi-
cation of diseases, ninth revision, clinical modification) 
diagnosis code 290-319. If the diagnosis date was 
recorded within a respective risk window, we consid-
ered the mother to have a psychiatric disorder.
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Follow-up
The follow-up period for all liveborn children started on 
the date of delivery and ended on the date of ADHD 
diagnosis, date of first drug prescription for ADHD, date 
of death, or 31 December 2015, whichever came first.
Outcome definition
Study outcomes in the liveborn children were an ADHD 
diagnosis, registered as ICD-9-CM diagnosis code 314, or 
a prescription for an ADHD drug, namely methylpheni-
date or atomoxetine (British National Formulary chap-
ter 4.4), as recorded in CDARS, as these are the only 
available drugs for ADHD in Hong Kong.
Covariates
Data on maternal comorbidities and other drugs were 
obtained from CDARS. As with previous studies,6-10 
covariates considered for confounding adjustment were 
maternal age at delivery, infant’s sex, birth year, birth 
hospital, parity, maternal underlying medical condi-
tions before delivery (pre-existing diabetes, epilepsy, 
gestational diabetes, psychiatric conditions, hyperten-
sion), use of other psychotropic drugs (antipsychotics, 
British National Formulary chapter 4.2.1, 4.2.2), and 
socioeconomic status.
statistical analysis
We adopted several approaches for analysis. For the first 
we compared ADHD status of children whose mothers 
used antidepressants during pregnancy (gestational 
users) with children whose mothers did not (non-gesta-
tional users). Hazard ratios for the association between 
antidepressant use for each trimester and outcome were 
estimated using Cox proportional hazard regression 
models. Robust standard error was used to adjust for 
data clustering. We selected the previously described 
covariates and added them to analytical models.
As the likelihood of being treated with antidepres-
sants might be higher in mothers with severe psychiat-
ric disorders, we carried out three levels of adjustment 
to assess the effect of confounding by indication. The 
first model (model 1) included all the covariates men-
tioned except for maternal underlying psychiatric ill-
ness and other psychotropic drug use before and during 
pregnancy. Model 2 extended model 1 to include all 
maternal underlying psychiatric disorders. Model 3 
added to model 2 by further adjusting for concurrent 
use of other psychotropic drugs. To investigate class 
effects we repeated the analyses and split the antide-
pressants into subgroups (SSRIs and non-SSRIs).
In another approach we explored the impact of con-
founding by indication. Firstly, we compared precon-
ception users of antidepressants (women who stopped 
treatment before conception) with never users. We 
restricted the cohort to mothers who neither used 
 antidepressants nor antipsychotics during pregnancy. 
Mothers who had only used antidepressants before 
pregnancy were defined as the preconception group, 
which acted as a negative control group 1. An increased 
risk of ADHD in the offspring of mothers among the 
 preconception group might indicate confounding by 
indication as the fetus was not exposed to antidepres-
sants. Similarly, mothers with gestational use of antide-
pressants were compared with the preconception group 
to assess if there is a difference in risk of ADHD in chil-
dren. Secondly, we assessed the association between 
maternal psychiatric disorders and risk of ADHD in chil-
dren. The analysis was restricted to mothers with a psy-
chiatric diagnosis who had never used antidepressants 
or antipsychotics before delivery (never users), this 
acted as negative control group 2. This allowed us to 
estimate the role of maternal psychiatric disorder in 
ADHD in their offspring. If a psychiatric disorder in 
mothers is associated with risk of ADHD in offspring, it 
is a confounder between prenatal use of antidepres-
sants and risk of ADHD. As a psychiatric disorder is an 
indication for antidepressants, this introduces the pos-
sibility of confounding by indication. Thirdly, we 
restricted the analysis to mothers who used either anti-
depressants or antipsychotics during pregnancy. We 
repeated the analyses by comparing use of SSRIs with 
use of non-SSRIs, and antidepressants with antipsy-
chotics using the method described previously. This 
analysis used the antipsychotic drug group as an active 
comparator group, to minimise the effect of confound-
ing by indication.
Several additional sensitivity analyses were con-
ducted to test the validity and robustness of the initial 
analyses. We carried out a sensitivity analysis by 
including children who were born after 1 January 2009 
to investigate the potential impact of under-diagnosis, 
because the rate of ADHD diagnosis among younger 
children has increased in recent years. Further analyses 
were conducted based on different drug non-adherence 
scenarios. To assess the effect of exposure misclassifica-
tion, we further extended each period of antidepressant 
use by adding 30 and 60 days to the end of each period. 
Children taking drugs for ADHD but without an ADHD 
diagnosis were removed from the analysis. We restricted 
the analyses to the first pregnancy only. This was to 
investigate the potential clustering effect of children 
who were born to the same mother. We conducted an 
additional sensitivity analysis by adjusting only for 
maternal depression, anxiety, and substance abuse dis-
order in our model. As ADHD is commonly diagnosed in 
children around the age of 5 years, we conducted a sen-
sitivity analysis by starting the follow-up time in chil-
dren at age 5 years. Children who had a diagnosis before 
age 5 were removed from this analysis.
We also conducted a post hoc sibling matched analy-
sis, a design that has been used previously to evaluate 
the association between smoking during pregnancy 
and risk of hyperkinetic disorder (a severe form of 
ADHD).20 This analysis was used to control for shared 
genetic and social confounding. We used stratified Cox 
regression with a separate stratum for each family 
 identified by the mother’s unique identification num-
ber. In the stratified Cox regression model, each family 
has its own baseline rate function reflecting the family’s 
shared genetic and social factors. The stratified Cox 
regression model is an extension of the paired binomial 
model, taking into account the differences in follow-up 
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time. Thus, only sibling pairs discordant for maternal 
antidepressant use and ADHD were able to contribute 
information to the estimates.
A significance level of 5% was used in all statistical 
analyses. Data manipulation and analysis were con-
ducted through Microsoft Excel and Statistical Analysis 
System (SAS) v9.3 (SAS Institute, Cary, NC). KM and WL 
carried out the analyses in parallel and independently. 
They cross checked the programming and results for 
accuracy and consistency.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community.
Results
The analysis included 190 618 pairs of mother-child 
records (fig 1 ). The mean maternal age at delivery was 
31.2 years (SD 5.1 years, table 1). Overall, 1252 children 
were exposed to maternal antidepressants during gesta-
tion. Among their mothers, 425 and 470 received SSRI 
and non-SSRI antidepressant monotherapy, respectively, 
129 received SSRIs and non-SSRIs, 101 received SSRIs 
and antipsychotics, 91 received non-SSRIs and antipsy-
chotics, and 36 received SSRIs, non-SSRIs, and antipsy-
chotics. Of 2275 mothers who received antidepressants 
before pregnancy; 1486 had discontinued treatment 
before pregnancy and 789 had continued treatment into 
pregnancy (see supplementary material 1 and 2).
In this cohort, 5659 children had a diagnosis of ADHD 
or received a drug for ADHD. The mean follow-up time 
was 9.28 years (range 7.4-11.0 years). The crude hazard 
ratio of antidepressant use during pregnancy and 
ADHD was 2.26 when gestational users were compared 
with non-gestational users. The estimate was similar in 
model 1 (adjusted hazard ratio 2.39, 95% confidence 
interval 1.90 to 3.02) but reduced to 1.41 (1.08 to1.83) and 
1.39 (1.07 to 1.82) in models 2 and 3, respectively, when 
maternal psychiatric disorder and additional psycho-
tropic drugs were included. The corresponding hazard 
ratios in the three trimesters were similar; the fully 
adjusted hazard ratios (model 3) were 1.43 (95% confi-
dence interval 1.05 to 1.95) for the first trimester, 1.50 
(1.08 to 2.09) for the second trimester, and 1.43 (1.03 to 
1.98) for the third trimester (table 2  and fig 2).
Results differed slightly when antidepressants were 
broken down into SSRIs and non-SSRIs. The hazard 
ratios for both were similar in the crude estimate and 
model 1 but different in models 2 and 3. In model 3, the 
adjusted hazard ratio for SSRIs was 1.11 (95% confidence 
interval 0.77 to 1.60), whereas for non-SSRIs it was 1.59 
(1.19 to 2.14). Table 2  and figure 2 summarise the results.
Comparisons
Preconception users (negative control group 1) versus 
never users—in model 3 the crude hazard ratio when 
preconception users of antidepressants were com-
pared with never users was 2.91 and the adjusted haz-
ard ratio was 1.76 (95% confidence interval 1.36 to 
2.30). The risk of ADHD in offspring was statistically 
significantly increased in preconception users (table 3 
and fig 3).
Never users with psychiatric disorders (negative con-
trol group 2) versus never users without psychiatric disor-
ders—when the analysis was restricted to mothers who 
had never used antidepressants or antipsychotics, the 
risk of ADHD in offspring was higher in mothers with 
psychiatric disorders. The fully adjusted hazard ratio 
for psychiatric disorders before pregnancy was 1.94 
(95% confidence interval 1.61 to 2.35) and during preg-
nancy was 1.84 (1.54 to 2.18). The risk estimates were 
similar to those for both preconception users and cur-
rent users (table 3  and fig 3).
Gestational use of antidepressants versus antipsychot-
ics (active comparator group)—gestational use of anti-
depressants yielded a crude hazard ratio of 1.15 for risk 
of ADHD in offspring compared with prenatal use of 
antipsychotic (fully adjusted hazard ratio 1.27, 95% con-
fidence interval 0.73 to 2.18). The comparison between 
use of SSRI and non-SSRI antidepressants showed no 
statistically significant difference between the two drug 
classes, with a crude hazard ratio of 0.75 and fully 
adjusted hazard ratio of 0.70 (95% confidence interval 
0.38 to 1.29) for risk of ADHD (table 3  and fig 4).
Gestational use of antidepressants versus preconcep-
tion users—in model 3 the crude hazard ratio when 
gestational users of antidepressants were compared 
with preconception users was 0.81 and the adjusted 
hazard ratio was 0.75 (95% confidence interval 0.51 to 
1.10). There was no statistically significant difference 
in the risk of ADHD in offspring between gestational 
users of antidepressants and preconception users 
(table 3  and fig 4).
sensitivity analyses
All other sensitivity analyses returned results similar to 
those of the main analyses (see supplementary material 
3 to 8).
Mother-child pairs with valid identication number (n=197 694)
Mother-child pairs included (n=190 618)
Mothers who used
antidepressants or
antipsychotics during
pregnancy (n=1616)
Mothers who did not use
antidepressants or
antipsychotics during
pregnancy (n=189 002)
Excluded (n=7076):
  Perinatal death (n=303)
  Abortion case (n=1)
  Birth with missing gestation week (n=157)
  Children with missing sex (n=27)
  Children with missing Apgar score at
    1 minute or 5 minutes (n=368)
  Pairs with date of conception outside study
    period (n=6220)
Fig 1 | Flowchart of mother-child pairs identification
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sibling matched analysis
The sibling matched analysis included 53 616 children 
of 26 049 mothers. In this subgroup, 1510 children had 
ADHD. There was no statistically significant difference 
in the risk of ADHD in siblings of mothers who were ges-
tational users of antidepressants compared with 
non-gestational users (adjusted hazard ratio 0.54, 0.17 
to 1.74).
discussion
This cohort study of more than 190 000 mother-child 
pairs in the Hong Kong Clinical Data Analysis and 
Reporting System (CDARS) database, found that prena-
tal use of antidepressants is associated with an 
increased risk of ADHD. The risk of ADHD was, how-
ever, similarly increased for preconception use of anti-
depressants (negative control group 1) and in children 
of mothers with psychiatric disorders who had not used 
antidepressants (negative control group 2). Further-
more, direct comparisons between the gestational user 
group and an active antipsychotic comparator group, 
the combined negative control groups 1 and 2, and the 
sibling matched non-gestational user group yielded sta-
tistically non-significant results.
Comparison with other studies
Most of the published population based studies, with 
the exception of Castro et al,8  reported similar results 
for risk of ADHD with prenatal use of antidepressants, 
ranging from 1.16 to 1.81.6-11  Preconception use of anti-
depressants (negative control group 1) is unlikely to 
contribute to intrauterine exposure and thus it is not 
plausible that such use is causally associated with 
ADHD in offspring. Based on the observed positive asso-
ciation between the negative control groups and the 
increased risk of ADHD in offspring, it is likely that the 
table 1 | Characteristics of children and their mothers by gestational drug use. values are numbers (percentages) unless stated otherwise
Characteristics
antidepressants 
(n=1024)
antipsychotics 
(n=364)
antidepressants 
and antipsychotics 
(n=228)
no antidepressants 
or antipsychotics 
(n=189 002)
Children
Mean (SD) follow-up time (patient years) 8.9 (2.2) 9.5 (2.4) 8.9 (2.2) 9.3 (2.2)
Attention-deficit/hyperactivity disorder 58 (5.7) 21 (5.8) 16 (7.0) 5564 (2.9)
Boy 552 (53.9) 192 (52.8) 122 (53.5) 98 316 (52.0)
Spontaneous vaginal delivery 670 (65.4) 233 (64.0) 136 (59.7) 123 834 (65.5)
Multiple pregnancy 22 (2.1) 4 (1.1) 4 (1.8) 5466 (2.9)
Birth trauma 4 (0.4) 1 (0.3) 1 (0.4) 862 (0.5)
Timing of Apgar score <7:
 1 minute 44 (4.3) 22 (6.0) 22 (9.6) 6983 (3.7)
 5 minutes 3 (0.3) 1 (0.3) 3 (1.3) 591 (0.3)
Birth weight (g):
 <1500 13 (1.3) 7 (1.9) 4 (1.8) 2213 (1.2)
 1500-2499 92 (9.0) 28 (7.7) 26 (11.4) 14 291 (7.6)
 ≥2500 919 (89.7) 329 (90.4) 198 (86.8) 172 498 (91.3)
Gestation weeks:
 <33 17 (1.7) 12 (3.3) 5 (2.2) 3502 (1.9)
 33-36 95 (9.3) 32 (8.8) 29 (12.7) 12 753 (6.8)
 >36 912 (89.1) 320 (87.9) 194 (85.1) 172 747 (91.3)
Mothers
Mean (SD) maternal age at delivery (years) 32.3 (5.53) 31.7 (5.60) 32.3 (6.05) 31.2 (5.10)
Maternal underlying conditions:
 Epilepsy 6 (0.6) 1 (0.3) 1 (0.4) 299 (0.16)
 Diabetes mellitus before pregnancy 9 (0.9) 2 (0.6) 3 (1.3) 444 (0.2)
 Gestational diabetes mellitus 45 (4.4) 26 (7.1) 16 (7.0) 5112 (2.7)
 Hypertension 43 (4.2) 17 (4.7) 10 (4.4) 6393 (3.4)
 Psychiatric illness 713 (69.6) 308 (84.6) 185 (81.1) 2978 (1.6)
Use of psychiatric drugs prepregnancy:
 Antidepressants 612 (59.8) 56 (15.4) 177 (77.6) 1430 (0.8)
 Antipsychotics 95 (9.3) 287 (78.9) 161 (70.6) 445 (0.2)
Parity:
 0 328 (32.0) 183 (50.3) 92 (40.4) 97 599 (51.6)
 1 425 (41.5) 102 (28.0) 76 (33.3) 70 962 (37.6)
 2 182 (17.8) 51 (14.0) 43 (18.9) 16 023 (8.5)
 ≥3 89 (8.7) 28 (7.7) 17 (7.5) 4418 (2.3)
Median household income (HK$)
 <19 300 199 (19.4) 93 (25.6) 39 (17.1) 37 828 (20.0)
 19 300-21 999 376 (36.7) 117 (32.1) 85 (37.3) 54 675 (28.9)
 22 000-25 999 226 (22.1) 88 (24.2) 56 (24.6) 46 018 (24.4)
 ≥26 000 223 (21.8) 66 (18.1) 48 (21.1) 50 481 (26.7)
HK$1 (£0.10; $0.13; €0.12).
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increased risk from prenatal use might at least be par-
tially explained by confounding due to pre-existing 
conditions of the mothers. ADHD is highly heritable,21 22 
and parents of children with ADHD are themselves 
more likely to have the same or related mental  disorders. 
In recent years it has become apparent that although 
ADHD often persists into adulthood and is associated 
with high levels of psychiatric comorbidity, including 
increased rates of depression and anxiety, many adults 
with ADHD never receive a proper diagnosis or 
 treatment.23 This could explain why we found a possi-
ble link between preconception use, psychiatric disor-
ders in mothers, and ADHD in children. Indeed, this 
study also found that mothers in both negative control 
groups are at similar increased risk of having offspring 
with ADHD as the mothers in the gestational treatment 
group. As psychiatric diseases are the main indication 
for prescription of antidepressants, our results suggest 
the possibility of confounding by  indication.
About 0.7% of children (1252 out of 190 618) in our 
cohort were exposed to antidepressant prenatally, 
which is slightly lower than in previous studies.6-10 
Comparing standardised differences in the rate of anti-
depressant use between the current study and previous 
studies (see supplementary material 9), our rate is 
lower than one study only7  and comparable with five 
other studies.6-11  In a previous drug prevalence study in 
Hong Kong, the prescribing prevalence was generally 
lower than in Western countries.24  This may be 
explained by the conservative approach in local prac-
tice.24 25 Nevertheless, there is no reason why these dif-
ferences in rates of antidepressant use should alter the 
conclusions of the study.
Many previous studies did not explore class and drug 
specific associations.6-11 In the current study we identi-
fied a slightly different result in our subgroup analysis 
on SSRIs and non-SSRIs, with no statistically significant 
association between prenatal use of SSRIs and risk of 
ADHD in children, although we cannot exclude the pos-
sibility of type 2 error. However, the difference in results 
between the SSRI and non-SSRI group may suggest the 
potential effect of disease severity rather than a differen-
tial effect of drug class. SSRIs are usually the first line 
treatment and thus mothers who use non-SSRIs during 
pregnancy may have more severe psychiatric conditions. 
table 2 | results from analysis comparing gestational users of antidepressants with non-gestational users
exposures
Crude estimate Model 1* Model 2† Model 3‡
Hazard ratio 
(95% Ci) P value
Hazard ratio  
(95% Ci) P value
Hazard ratio  
(95% Ci) P value
Hazard ratio  
(95% Ci) P value
Antidepressants§:
 During pregnancy 2.26 (1.80 to 2.84) <0.01 2.39 (1.90 to 3.02) <0.01 1.41 (1.08 to 1.83) 0.01 1.39 (1.07 to 1.82) 0.01
 1st trimester 2.29 (1.74 to 3.03) <0.01 2.45 (1.85 to 3.25) <0.01 1.48 (1.09 to 2.00) 0.01 1.43 (1.05 to 1.95) 0.02
 2nd trimester 2.41 (1.78 to 3.26) <0.01 2.65 (1.96 to 3.59) <0.01 1.51 (1.09 to 2.10) 0.01 1.50 (1.08 to 2.09) 0.02
 3rd trimester 2.37 (1.76 to 3.17) <0.01 2.55 (1.90 to 3.42) <0.01 1.40 (1.01 to 1.93) 0.04 1.43 (1.03 to 1.98) 0.03
SSRIs¶:
 During pregnancy 2.17 (1.56 to 3.03) <0.01 2.23 (1.60 to 3.12) <0.01 1.23 (0.86 to 1.77) 0.26 1.11 (0.77 to 1.60) 0.57
 1st trimester 2.21 (1.49 to 3.27) <0.01 2.32 (1.57 to 3.45) <0.01 1.31 (0.86 to 1.98) 0.21 1.18 (0.78 to 1.80) 0.43
 2nd trimester 2.11 (1.31 to 3.41) <0.01 2.22 (1.37 to 3.60) <0.01 1.20 (0.72 to 1.98) 0.48 1.10 (0.66 to 1.83) 0.71
 3rd trimester 2.21 (1.38 to 3.50) <0.01 2.26 (1.41 to 3.63) <0.01 1.19 (0.73 to 1.93) 0.48 1.16 (0.71 to 1.88) 0.56
Non-SSRIs**:
 During pregnancy 2.56 (1.95 to 3.35) <0.01 2.76 (2.10 to 3.62) <0.01 1.63 (1.22 to 2.19) <0.01 1.59 (1.19 to 2.14) <0.01
 1st trimester 2.57 (1.82 to 3.64) <0.01 2.80 (1.96 to 3.99) <0.01 1.73 (1.20 to 2.49) <0.01 1.64 (1.13 to 2.38) <0.01
 2nd trimester 2.70 (1.88 to 3.86) <0.01 3.04 (2.12 to 4.38) <0.01 1.75 (1.19 to 2.55) <0.01 1.72 (1.16 to 2.53) <0.01
 3rd trimester 2.70 (1.91 to 3.83) <0.01 2.96 (2.08 to 4.20) <0.01 1.62 (1.12 to 2.35) 0.01 1.65 (1.13 to 2.40) <0.01
SSRI=selective serotonin reuptake inhibitor.
*Adjusted for maternal age at delivery, infant’s sex, birth year, birth hospital, parity, maternal underlying illness before delivery (pre-existing diabetes, epilepsy, gestational diabetes, 
hypertension), and socioeconomic status.
†Adjusted for all factors in model 1 and maternal psychiatric conditions.
‡Adjusted for all factors in model 2 and other psychiatric drug use.
§ADHD cases: 74 in antidepressant users, 5564 in non-users.
¶ADHD cases: 18 in SSRI users, 5564 in non-users.
**ADHD cases: 31 in non-SSRI users, 5564 in non-users.
None
Antidepressants
  During pregnancy
  1st trimester
  2nd trimester
  3rd trimester
SSRIs
  During pregnancy
  1st trimester
  2nd trimester
  3rd trimester
Non-SSRIs
  During pregnancy
  1st trimester
  2nd trimester
  3rd trimester
1.39 (1.07 to 1.82)
1.43 (1.05 to 1.95)
1.50 (1.08 to 2.09)
1.43 (1.03 to 1.98)
1.11 (0.77 to 1.60)
1.18 (0.78 to 1.80)
1.10 (0.66 to 1.83)
1.16 (0.71 to 1.88)
1.59 (1.19 to 2.14)
1.64 (1.13 to 2.38)
1.72 (1.16 to 2.53)
1.65 (1.13 to 2.40)
0.01
0.02
0.02
0.03
0.57
0.43
0.71
0.56
<0.01
<0.01
<0.01
<0.01
0 1 2 3
Gestational
drug use
Decreased
risk of ADHD
Increased
risk of ADHD
Fully adjusted hazard
ratio (95% CI)
Fully adjusted hazard
ratio (95% CI)
P
value
5564
74
18
31
No of
cases
Fig 2 | Fully adjusted results from analysis for gestational users of antidepressants 
compared with non-gestational users. ssri=selective serotonin reuptake inhibitor; 
aDHD=attention-deficit/hyperactivity disorder
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This might explain the difference in the result, although 
further studies should evaluate if the corresponding risk 
differs between SSRI and non-SSRI antidepressants.
The results of one study8  differed from those of previ-
ous studies even though this was a replication study 
using the same data source and similar methods.10 The 
study reported no statistically significant increase in risk 
associated with prenatal use of antidepressants but did 
find an increased risk associated with prepregnancy anti-
depressant use. The authors suggest that it is therefore 
possible that the association between antidepressant use 
and ADHD in offspring might be indicative of confound-
ing by indication. It is, however, difficult to explain why 
confounding by indication should only occur for prepreg-
nancy antidepressant use and not prenatal use. In con-
trast, our study has shown consistent results for 
gestational users (active treatment group) in the three 
trimesters, preconception users (negative  control group 
1), and never users with a psychiatric diagnosis (negative 
control group 2). Our study therefore provides stronger 
evidence to support the possibility that the observed asso-
ciations might represent confounding by indication.
strengths and limitations of this study
The novelty of the current study is that we utilised two 
complementary planned negative control groups. An 
increased risk of ADHD was observed in children whose 
mothers had used antidepressants before conception 
(negative control group 1) and those mothers with a psy-
chiatric diagnosis who had never used antidepressants 
(negative control group 2). Although it is difficult to adjust 
for confounding by indication in the classic population 
based analysis, the outcomes of the two negative control 
analyses aid the interpretation of our results. To further 
explore the possibility of confounding by indication, we 
preselected mothers who used antipsychotic drugs as an 
active comparator group, and the lack of association in 
this analysis adds further weight to the interpretation. 
Finally, we also conducted a sibling matched analysis 
using sibling pairs. Although we cannot exclude the pos-
sibility of type 2 error in this analysis, the results further 
strengthen our hypothesis that confounding by indica-
tion may play a major role in the observed positive associ-
ation between gestational use of antidepressants and 
ADHD in offspring. We have not been able to identify any 
other published studies that have applied such a compre-
hensive series of analyses to these associations. We rec-
ommend that this approach should be considered in 
future studies that investigate gestational drug use and 
outcome in offspring, particularly diseases and disorders 
with high heritability and that are therefore more likely to 
be confounded by indication.
Previous studies have been based in Scandinavian 
countries and North America, countries with a large 
population of white people. Our study is the first based 
in Asia. After adjusting for confounding factors, our 
comprehensive analyses in a predominately Chinese 
population yielded similar results to a recently pub-
lished Swedish study using population based and sib-
ling based analyses. Both studies do not support 
gestational antidepressant use as significantly t
ab
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 increasing the risk of ADHD in offspring. As the two 
study populations have a different genetic composi-
tion, healthcare systems, and environments, this sug-
gests the findings are broadly generalisable to other 
populations.
This study also has several important weaknesses. A 
limitation of register based studies is that they only 
include cases that are clinically detected. In our cohort, 
about 3% of children had a diagnosis of ADHD or used 
ADHD treatment, which is lower than the prevalence 
estimates from epidemiological studies (5-7%). How-
ever, it is generally accepted that for most non-US coun-
tries the administrative prevalence (number of ADHD 
cases that are diagnosed and treated) is somewhat lower 
than the epidemiological prevalence.26 Under-diagnosis 
of less severe cases of ADHD is likely to be the same 
across the groups; hence it is unlikely to have affected 
the findings or conclusions of the current study.
CDARS only contains information from publicly 
funded healthcare medical records and therefore does 
not include data from private medical practitioners or 
hospitals. Based on the birth statistics in Hong Kong, 
about 45 000 live births occurred in 2009.27  Our data 
captured more than 31 000 birth events in the same 
year, thus including about 70% of births in Hong 
Kong.27  Notably, the public sector is the main provider 
of specialist care for neurodevelopmental disorders in 
Hong Kong.28 Children with neurodevelopmental disor-
ders usually require comprehensive long term treat-
ment and monitoring, hence they are usually under the 
care of publicly funded healthcare. It is therefore likely 
that most of the children who received a diagnosis of 
ADHD will have been included in this study.
As antidepressant use is defined by prescriptions 
written by clinicians and dispensed by pharmacies, it is 
unclear whether the drugs were actually taken by 
women in accordance with information on the prescrip-
tion (adherence)—that is, use of the drugs might have 
been longer than the intended prescribing period. We 
addressed usage misclassification by conducting a dura-
tion-outcome analysis, adding 30 and 60 days after the 
end of the expected period for antidepressant use. How-
ever, we could not exclude the possibility that included 
mothers might obtain prescriptions for antidepressant 
from the private sector, which we would not be able to 
identify; although the public sector is by far the main 
provider of specialist care in Hong Kong. Thus the poten-
tial for missing drug records is minimal. Drug usage mis-
classification will bias the risk estimate towards the 
null. We may potentially underestimate the risk but this 
would not affect the conclusions of the study.
Policy implications
Since the first report of a possible association between 
in utero exposure to antidepressants and neurodevel-
opmental disorders in children, both patients and clini-
cians have faced the dilemma of how to manage women 
with severe affective disorders both when they are try-
ing to conceive and when they are pregnant. Major 
adverse effects can occur when stopping drugs abruptly 
or withholding antidepressants during pregnancy. The 
present findings provide useful data to help guide clini-
cians in decision making.
Conclusions
Previous reports might have overestimated the associa-
tion between gestational use of antidepressants and 
ADHD in offspring because they have failed to control 
for shared family factors. Although we cannot com-
pletely discount the possibility that gestational use of 
antidepressants is a causal factor, our findings raise the 
possibility that confounding by indication might at least 
partially explain the observed association. We propose 
that if a causal association exists, then the size of the 
effect is probably smaller than that previously reported. 
However, decision making about antidepressant use in 
pregnancy remains important and requires an assess-
ment of the risks and benefits in the context of the indi-
vidual woman and family.
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